Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Grignani

Showing results (1-10 of 173) with videos related to

Pageof 18
Sort By:
Giornale Di Clinica Medica|July 1, 1974
[Indications for transfusion therapy in hemoblastoses]F Grignani
Critical Reviews in Oncology/Hematology|January 1, 1985
Chronic myelogenous leukemiaF Grignani
Leukemia|September 1, 1995
The acute promyelocytic leukemia-specific PML/RAR alpha fusion protein reduces the frequency of commitment to apoptosis upon growth factor deprivation of GM-CSF-dependent myeloid cellsD Rogaia, F Grignani, F Grignani, et al.
Current Topics in Microbiology and Immunology|January 1, 1996
Pathogenetic role of the PML1RAR alpha fusion protein in acute promyelocytic leukemiaF Grignani, P G Pelicci
Haematologica|June 1, 1991
[Molecular biology in onco-hematology]P G Pelicci, F Grignani
Current Opinion in Oncology|October 1, 1989
Molecular biology of lymphoid malignanciesF Grignani, R Dalla-Favera
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 1, 1984
Intrapericardial tetracycline sclerosis in the treatment of malignant pericardial effusion: an analysis of thirty-three casesS Davis, P Rambotti, F Grignani
La Clinica Terapeutica|April 30, 1974
[Antimetabolites in the treatment of acute human leukoses. Mechanism of action and conditioning factors in the cellular response to drugs. II]F Grignani, M Martelli, M Tonato
Lancet (London, England)|February 6, 1993
Immunotherapy: what are we administering to the allergic patient?F Spinozzi, E Cimignoli, F Grignani
La Clinica Terapeutica|April 15, 1974
[Antimetabolites in the therapy of acute human leukoses. Mechanism of action and conditioning factors in the cellular response to drugs. I]F Grignani, M Martelli, M Tonato
Pageof 18

Showing results (1-10 of 173) with videos related to

Sort By:
Pageof 18
Giornale Di Clinica Medica|July 1, 1974
[Indications for transfusion therapy in hemoblastoses]F Grignani
Critical Reviews in Oncology/Hematology|January 1, 1985
Chronic myelogenous leukemiaF Grignani
Leukemia|September 1, 1995
The acute promyelocytic leukemia-specific PML/RAR alpha fusion protein reduces the frequency of commitment to apoptosis upon growth factor deprivation of GM-CSF-dependent myeloid cellsD Rogaia, F Grignani, F Grignani, et al.
Current Topics in Microbiology and Immunology|January 1, 1996
Pathogenetic role of the PML1RAR alpha fusion protein in acute promyelocytic leukemiaF Grignani, P G Pelicci
Haematologica|June 1, 1991
[Molecular biology in onco-hematology]P G Pelicci, F Grignani
Current Opinion in Oncology|October 1, 1989
Molecular biology of lymphoid malignanciesF Grignani, R Dalla-Favera
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 1, 1984
Intrapericardial tetracycline sclerosis in the treatment of malignant pericardial effusion: an analysis of thirty-three casesS Davis, P Rambotti, F Grignani
La Clinica Terapeutica|April 30, 1974
[Antimetabolites in the treatment of acute human leukoses. Mechanism of action and conditioning factors in the cellular response to drugs. II]F Grignani, M Martelli, M Tonato
Lancet (London, England)|February 6, 1993
Immunotherapy: what are we administering to the allergic patient?F Spinozzi, E Cimignoli, F Grignani
La Clinica Terapeutica|April 15, 1974
[Antimetabolites in the therapy of acute human leukoses. Mechanism of action and conditioning factors in the cellular response to drugs. I]F Grignani, M Martelli, M Tonato
Pageof 18